TABLE 6

Summary of Results of Studies Reporting on Individualized Outcomes

StudyOutcomeTiming, wknTreatment, Mean (±SD)nControl, Mean (±SD)SMD (95% CI)P
NDT
 Law et al13COPM-P16266.5 (1.6)245.7 (1.4)0.53 (−0.04 to 1.09)
406.1 (1.6)5.5 (1.7)0.36 (−0.20 to 0.92)
COPM-S16267.1 (1.9)245.8 (1.8)0.70 (0.12 to 1.26).02
406.7 (1.8)5.8 (1.7)0.51 (−0.06 to 1.07)
BoNT-A
 Lowe et al16COPM-P3214.5 (0.9)213.8 (1.4)0.59 (−0.03 to 1.20)
125.3 (1.4)4.5 (1.4)0.57 (−0.06 to 1.18)
265.9 (1.4)5.1 (2.3)0.42 (−0.20 to 1.02)
COPM-S 35.1 (1.4)4.1 (1.8)0.62 (−0.01 to 1.21)
125.8 (1.4)4.7 (1.8)0.68 (0.05 to 1.29).03
266.2 (1.4)5.4 (3)0.34 (−0.27 to 0.94)
GAS-family336.1 (10.1)27.1 (6.4)1.06 (0.40 to 1.69).00
1242 (10.1)34.1 (9.2)0.82 (0.17 to 1.43).01
2646.8 (10.5)40.1 (13.3)0.56 (−0.07 to 1.16)
GAS-ther357.8 (13.8)40.5 (11.9)0.94 (0.29 to 1.56).00
1261 (17.4)46.8 (12.4)0.62 (−0.01 to 1.23).05
2658.7 (15.6)49.9 (12.4)1.29 (0.63 to 1.96).00
 Kawamura et al17GAS121852.5 (9.0)2149.9 (10.5)0.26 (−0.38 to 0.90)
 Wallen et al18 (a)aCOPM-P12195.6 (1.4)154.4 (1.3)0.66 (−0.03 to 1.36).05
265.9 (1.8)5.1 (1.6)0.46 (−0.26 to 1.17)
COPM-S126.5 (1.7)5.4 (1.9)0.11 (−0.57 to 0.79)
266.8 (1.8)6.3 (1.9)0.27 (−0.44 to 0.97)
GAS1242.3 (13.7)32.9 (10.3)0.79 (0.08 to 1.49).02
2652.5 (13.3)40.6 (12.0)0.93 (0.20 to 1.62).01
 Wallen et al18 (b)bCOPM-P12205.4 (2.1)175.6 (1.8)−0.1 (−0.75 to 0.55)
265.8 (2)6.2 (1.8)−0.21 (−0.85 to 0.44)
COPM-S126.6 (2.1)6.1 (1.9)0.24 (−0.41 to 0.89)
266.6 (1.7)6.9 (2.1)−0.16 (−0.80 to 0.49)
GAS1251 (12.3)42.2 (10.6)0.98 (0.29 to 1.66).00
2651.7 (13.3)51.4 (11.1)0.02 (−0.62 to 0.67)
 Russo et al19GAS122144.6 (14.9)2231.6 (10.7)0.97 (0.34 to 1.60).00
2643.1 (19.2)39.2 (16.0)0.22 (−0.38 to 0.82)
 Olesch et al20COPM-P16114.9 (1.4)114.3 (1.4)0.48 (−0.39 to 131)
324.9 (1.5)4.4 (1.4)0.34 (−0.51 to 1.17)
484.3 (1.4)4.3 (1.4)0.58 (−0.30 to 1.41)
COPM-S165.2 (1.4)4.5 (1.5)0.48 (−0.38 to 1.31)
325.3 (1.7)4.5 (1.7)0.47 (−0.39 to 1.30)
485.2 (1.8)4.3 (1.5)0.54 (−0.33 to 1.30)
GAS1654.1 (9.8)48.1 (10.1)0.60 (−0.27 to 1.43)
3255 (4.3)47.3 (11.6)0.88 (−0.03 to 1.72).05
4854.9 (9.5)50 (7.1)0.58 (−0.29 to 1.41)
mCIMT
 Sakzewski et al32COPM-P3326.3 (1.9)316.3 (1.5)0.0 (−0.49 to 0.49)
266.1 (2.0)6.2 (1.7)−0.05 (−0.57 to 0.46)
526.5 (2.1)6.6 (1.7)−0.05 (−0.57 to 0.47)
COPM-S36.8 (2.0)7.0 (1.6)−0.11 (−0.60 to 0.39)
266.8 (2.2)6.8 (1.6)0.00 (−0.51 to 0.51)
527.2 (2.0)6.9 (2.1)0.15 (−0.38 to 0.67)
 Wallen et al37COPM-P10256.1 (2.3)256.0 (1.7)0.05 (−0.51 to 0.60)
266.8 (1.9)6.8 (1.5)0.00 (−0.55 to 0.55)
COPM-S106.5 (2.4)6.7 (2.2)−0.09 (−0.64 to 0.47)
267.2 (2.1)7.2 (2.0)0.00 (−0.55 to 0.55)
GAS100.5 (0.9)0.5 (0.8)0.00 (−0.55 to 0.55)
260.9 (0.9)0.8 (0.8)0.12 (−0.44 to 0.67)
 Gordon et al35 and de Brito Brandão et al36GAS0.32151(7.9)2159.1 (8.4)−0.99 (−1.61 to −0.33).00
454.5 (7.2)61.3 (7.2)−0.94 (−1.56 to −0.29).00
2659 (7.7)63.8 (7.5)−0.63 (−1.24 to 0.00).05
COPM-P0.185.5 (1.7)6.6 (1.2)−0.71 (−1.68 to 0.34)
COPM-S0.15.7 (2.1)6.8 (1.6)−0.59 (−1.56 to 0.44)
 Hoare et al47COPM-P4173.1 (1.7)173.4 (1.6)−0.16 (−0.83 to 0.51)
125.6 (2.3)5.5 (2.0)0.07 (−0.60 to 0.75)
265.5 (2.3)5.6 (1.8)−0.06 (−0.73 to 0.61)
COPM-S43.2 (1.9)3.6 (1.8)−0.21 (−0.88 to 0.47)
125.6 (2.5)5.5 (2.0)0.00 (−0.67 to 0.68)
265.6 (2.6)5.8 (2.2)−0.09 (−0.76 to 0.58)
Hybrid model: combined mCIMT and bimanual training
 Aarts et al8COPM-P9286.5 (1.0)244.6 (1.4)1.59 (0.91 to 2.21).00
176.5 (0.9)4.7 (1.4)1.57 (0.91 to 2.18).00
COPM-S97.4 (1.2)5.3 (1.2)1.75 (1.07 to 2.38).00
177.3 (1.2)5.5 (1.2)1.50 (0.85 to 2.11).00
ABILHAND928.4 (5.9)23.7 (6.0)0.79 (0.2 to 1.36).01
1728.9 (5.2)24.4 (6.6)0.77 (0.18 to 1.33).01
Other UL interventions
 Novak et al51 (a)cCOPM-P4124.3 (1.8)123.4 (1.5)0.54 (−0.29 to 1.34)
85.4 (1.9)3.4 (1.5)1.17 (0.27 to 1.99).01
COPM-S44.4 (2.3)3.6 (2.0)0.37 (−0.45 to 1.16)
85.4 (2.2)3.6 (2.0)0.86 (−0.01 to 1.66).05
GAS451.5 (13.9)26.0 (2.1)2.57 (1.41 to 3.54).00
860.7 (15.6)26.0 (2.1)3.12 (1.84 to 4.18).00
 Novak et al51 (b)dCOPM-P4114.8 (2.2)123.4 (1.5)0.75 (−0.12 to 1.57)
85.9 (2.2)3.4 (1.5)1.34 (0.39 to 2.19).00
COPM-S45.1 (1.8)3.6 (2.0)0.79 (−0.09 to 1.60)
86.1 (1.9)3.6 (2.0)1.28 (0.34 to 2.13).01
GAS447.1 (11.6)26.0 (2.1)2.59 (1.41 to 3.59).00
864.3 (15.4)26.0 (2.1)3.57 (2.15 to 4.73).00
 Elliott et al52GAS12853 (5)835 (6.8)3.02 (1.46 to 4.24).00
  • ABILHAND, ; GAS, Goal Attainment Scale; P, performance; S, satisfaction; ther, therapist.

  • a Wallen et al (a) BoNT-A and OT versus control.

  • b Wallen et al (b) BoNT-A and OT versus OT.

  • c Novak et al (a) 8 week OT Home program versus control.

  • d Novak et al (b) 4 week OT Home program versus control.